Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.
Avidicure has raised $50.0M in total funding. The most recent round was Seed. The last funding was announced in April 2025.
Avidicure's investors include EQT Life Sciences, Kurma Partners, V-Bio Ventures, BioGeneration Ventures, BOM.
Avidicure is headquartered in Oegstgeest, The Netherlands.
Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.
Avidicure is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Avidicure — Funding & Investors." VCBacked, April 24, 2025, https://www.vcbacked.co/company/avidicure. Accessed September 29, 2026.
VCBacked. (2025). Avidicure — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/avidicure
{{cite web |title=Avidicure — Funding & Investors |url=https://www.vcbacked.co/company/avidicure |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated